Literature DB >> 7839770

Inhaled nitric oxide lowers pulmonary capillary pressure and changes longitudinal distribution of pulmonary vascular resistance in patients with acute lung injury.

A Benzing1, K Geiger.   

Abstract

In acute lung injury (ALI), where pulmonary microvascular permeability is increased, transvascular fluid filtration depends mainly on the hydrostatic capillary pressure. In the presence of intrapulmonary vasoconstriction pulmonary capillary pressure (PCP) may increase thereby promoting transvascular fluid filtration and lung oedema formation. We studied the effect of 40 ppm inhaled nitric oxide (NO) on PCP and longitudinal distribution of pulmonary vascular resistance (PVR) in 18 patients with ALI. PCP was estimated by visual analysis of the pressure decay profile following pulmonary artery balloon inflation. Contribution of venous pulmonary resistance to total PVR was calculated as the percentage of the pressure gradient in the pulmonary venous system to the total pressure gradient across the lung. Inhalation of 40 ppm NO produced a prompt decrease in mean pulmonary artery pressure (PAP) from 34.1 +/- 6.8 to 29.6 +/- 5.7 (s.d.) mmHg; (P < 0.0001). PCP declined from 24.8 +/- 6.2 to 21.6 +/- 5.2 mmHg; (P < 0.0001) while pulmonary artery wedge pressure (PAWP) did not change. PVR decreased from 166 +/- 73 to 128 +/- 50 dyn.sec.cm-5; (P < 0.0001). Pulmonary venous resistance (PVRven) decreased to a greater extent (from 76 +/- 41 to 50 +/- 28 dyn.sec.cm-5; (P < 0.001) than pulmonary arterial resistance (PVRart) (from 90 +/- 36 to 79 +/- 29 dyn.sec.cm-5; (P < 0.01). The contribution of PVRven to PVR fell from 44.3 +/- 10.8 to 37.8 +/- 11.9%; (P < 0.01). Cardiac output (CO) remained constant. The findings demonstrate that NO has a predominant vasodilating effect on pulmonary venous vasculature thereby lowering PCP in patients with ALI.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7839770     DOI: 10.1111/j.1399-6576.1994.tb03970.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  8 in total

1.  Inhaled nitric oxide fraction is influenced by both the site and the mode of administration.

Authors:  E Sieffert; L Ducros; M R Losser; D M Payen
Journal:  J Clin Monit Comput       Date:  1999-12       Impact factor: 2.502

Review 2.  The use, and misuse, of exogenous endothelial-derived vasodilators in acute respiratory failure.

Authors:  A T Dinh-Xuan; F Brunet; J F Dhainaut
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

3.  Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale.

Authors:  Michael Hawkes; Robert Opika Opoka; Sophie Namasopo; Christopher Miller; Andrea L Conroy; Lena Serghides; Hani Kim; Nisha Thampi; W Conrad Liles; Chandy C John; Kevin C Kain
Journal:  Med Hypotheses       Date:  2011-07-13       Impact factor: 1.538

4.  Randomised trial of three doses of inhaled nitric oxide in acute respiratory distress syndrome.

Authors:  S F Tang; M C Sherwood; O I Miller
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

5.  Combined effects of NO inhalation and intravenous PGF2 alpha on pulmonary circulation and gas exchange in an ovine ARDS model.

Authors:  H Kobayashi; N Tanaka; M Winkler; W M Zapol
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

6.  Fluid management in acute lung injury and ards.

Authors:  Antoine Roch; Christophe Guervilly; Laurent Papazian
Journal:  Ann Intensive Care       Date:  2011-05-30       Impact factor: 6.925

7.  Inhaled nitric oxide reverses cell-free hemoglobin-induced pulmonary hypertension and decreased lung compliance. Preliminary results.

Authors: 
Journal:  Crit Care       Date:  1997       Impact factor: 9.097

Review 8.  Endothelial Damage in Acute Respiratory Distress Syndrome.

Authors:  Alice G Vassiliou; Anastasia Kotanidou; Ioanna Dimopoulou; Stylianos E Orfanos
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.